<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="10" family="AdvPSMy-B" color="#231f20"/>
	<fontspec id="font1" size="9" family="AdvC2866" color="#231f20"/>
	<fontspec id="font2" size="10" family="AdvPSMy-R" color="#231f20"/>
	<fontspec id="font3" size="9" family="AdvTimes" color="#231f20"/>
	<fontspec id="font4" size="9" family="AdvC2867" color="#231f20"/>
	<fontspec id="font5" size="9" family="AdvP4C4E74" color="#231f20"/>
	<fontspec id="font6" size="9" family="AdvPS586B" color="#231f20"/>
	<fontspec id="font7" size="8" family="AdvPSMy-R" color="#231f20"/>
<text top="50" left="45" width="58" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Introduction</text>
<text top="68" left="54" width="234" height="8" font="font1" id="p1_t2" reading_order_no="2" segment_no="3" tag_type="text">Two members of the lipase family, lipoprotein lipase (LPL)</text>
<text top="79" left="45" width="243" height="8" font="font1" id="p1_t3" reading_order_no="3" segment_no="3" tag_type="text">and hepatic lipase (HL) are known to inﬂuence plasma</text>
<text top="91" left="45" width="243" height="8" font="font1" id="p1_t4" reading_order_no="4" segment_no="3" tag_type="text">lipoprotein metabolism and risk of atherosclerosis in humans</text>
<text top="102" left="45" width="243" height="8" font="font1" id="p1_t5" reading_order_no="5" segment_no="3" tag_type="text">[1–5]. Endothelial lipase (EL) is a more recently discovered</text>
<text top="113" left="45" width="243" height="8" font="font1" id="p1_t6" reading_order_no="6" segment_no="3" tag_type="text">member of this family of lipases [6,7]. In contrast to LPL and</text>
<text top="124" left="45" width="243" height="8" font="font1" id="p1_t7" reading_order_no="7" segment_no="3" tag_type="text">HL, it is expressed in endothelial cells and, in the majority of</text>
<text top="135" left="45" width="243" height="8" font="font1" id="p1_t8" reading_order_no="8" segment_no="3" tag_type="text">reports, has relatively more phospholipase activity than the</text>
<text top="146" left="45" width="243" height="8" font="font1" id="p1_t9" reading_order_no="9" segment_no="3" tag_type="text">other two enzymes. Similar to HL and LPL, it is secreted and</text>
<text top="157" left="45" width="243" height="8" font="font1" id="p1_t10" reading_order_no="10" segment_no="3" tag_type="text">binds to the endothelial surface. In vitro, EL effectively</text>
<text top="168" left="45" width="243" height="8" font="font1" id="p1_t11" reading_order_no="11" segment_no="3" tag_type="text">hydrolyzes high-density lipoprotein (HDL) phospholipids. In</text>
<text top="179" left="45" width="243" height="8" font="font1" id="p1_t12" reading_order_no="12" segment_no="3" tag_type="text">mice, EL has a major inﬂuence on HDL metabolism.</text>
<text top="190" left="45" width="243" height="8" font="font1" id="p1_t13" reading_order_no="13" segment_no="3" tag_type="text">Adenovirally mediated overexpression of human EL in mice</text>
<text top="201" left="45" width="243" height="8" font="font1" id="p1_t14" reading_order_no="14" segment_no="3" tag_type="text">dramatically reduced HDL cholesterol (HDL-C) concentra-</text>
<text top="212" left="45" width="243" height="8" font="font1" id="p1_t15" reading_order_no="15" segment_no="3" tag_type="text">tions [6], shown to be due to rapid catabolism of HDL [8].</text>
<text top="224" left="45" width="243" height="8" font="font1" id="p1_t16" reading_order_no="16" segment_no="3" tag_type="text">Transgenic overexpression of human EL was shown to reduce</text>
<text top="235" left="45" width="243" height="8" font="font1" id="p1_t17" reading_order_no="17" segment_no="3" tag_type="text">HDL-C concentrations as well [9]. Conversely, antibody</text>
<text top="246" left="45" width="243" height="8" font="font1" id="p1_t18" reading_order_no="18" segment_no="3" tag_type="text">inhibition of EL in mice signiﬁcantly increased HDL-C</text>
<text top="257" left="45" width="243" height="8" font="font1" id="p1_t19" reading_order_no="19" segment_no="3" tag_type="text">concentrations [10], and EL knockout mice have a signiﬁcant</text>
<text top="268" left="45" width="243" height="8" font="font1" id="p1_t20" reading_order_no="20" segment_no="3" tag_type="text">increase in HDL-C concentrations [9,11]. Furthermore, EL</text>
<text top="279" left="45" width="243" height="8" font="font1" id="p1_t21" reading_order_no="21" segment_no="3" tag_type="text">knockout mice crossed onto the apolipoprotein E knockout</text>
<text top="290" left="45" width="243" height="8" font="font1" id="p1_t22" reading_order_no="22" segment_no="3" tag_type="text">background have decreased atherosclerosis [12]. Based on</text>
<text top="301" left="45" width="243" height="8" font="font1" id="p1_t23" reading_order_no="23" segment_no="3" tag_type="text">these studies in mice, it has been suggested that EL may be an</text>
<text top="312" left="45" width="243" height="8" font="font1" id="p1_t24" reading_order_no="24" segment_no="3" tag_type="text">important risk factor and may affect the development of</text>
<text top="323" left="45" width="106" height="8" font="font1" id="p1_t25" reading_order_no="25" segment_no="3" tag_type="text">atherosclerosis in humans.</text>
<text top="335" left="54" width="234" height="8" font="font1" id="p1_t26" reading_order_no="26" segment_no="7" tag_type="text">The relationship of EL to variation in lipoprotein concen-</text>
<text top="346" left="45" width="243" height="8" font="font1" id="p1_t27" reading_order_no="27" segment_no="7" tag_type="text">trations and atherosclerosis in humans has not been</text>
<text top="357" left="45" width="243" height="8" font="font1" id="p1_t28" reading_order_no="28" segment_no="7" tag_type="text">reported. Several genetic association studies have suggested</text>
<text top="368" left="45" width="243" height="8" font="font1" id="p1_t29" reading_order_no="29" segment_no="7" tag_type="text">that rare variants and common polymorphisms in the human</text>
<text top="379" left="45" width="243" height="8" font="font1" id="p1_t30" reading_order_no="30" segment_no="7" tag_type="text">EL gene might be associated with variation in HDL-C</text>
<text top="390" left="45" width="243" height="8" font="font1" id="p1_t31" reading_order_no="31" segment_no="7" tag_type="text">concentrations [11,13,14], but they have not been conclusive</text>
<text top="401" left="45" width="243" height="8" font="font1" id="p1_t32" reading_order_no="32" segment_no="7" tag_type="text">and were not accompanied by direct measurement of EL</text>
<text top="412" left="45" width="243" height="8" font="font1" id="p1_t33" reading_order_no="33" segment_no="7" tag_type="text">concentrations. We hypothesized that concentrations of EL</text>
<text top="423" left="45" width="243" height="8" font="font1" id="p1_t34" reading_order_no="34" segment_no="7" tag_type="text">are inversely associated with HDL-C concentrations and</text>
<text top="434" left="45" width="243" height="8" font="font1" id="p1_t35" reading_order_no="35" segment_no="7" tag_type="text">directly associated with the metabolic syndrome and athero-</text>
<text top="445" left="45" width="243" height="8" font="font1" id="p1_t36" reading_order_no="36" segment_no="7" tag_type="text">sclerosis in humans. To test this, we developed an immuno-</text>
<text top="457" left="45" width="243" height="8" font="font1" id="p1_t37" reading_order_no="37" segment_no="7" tag_type="text">assay for human EL and used it to measure EL mass</text>
<text top="468" left="45" width="243" height="8" font="font1" id="p1_t38" reading_order_no="38" segment_no="7" tag_type="text">concentrations in both pre-heparin and post-heparin plasma</text>
<text top="479" left="45" width="243" height="8" font="font1" id="p1_t39" reading_order_no="39" segment_no="7" tag_type="text">samples in individuals enrolled in the Study of the Inherited</text>
<text top="490" left="45" width="243" height="8" font="font1" id="p1_t40" reading_order_no="40" segment_no="7" tag_type="text">Risk of Atherosclerosis (SIRCA). We determined the associ-</text>
<text top="501" left="45" width="243" height="8" font="font1" id="p1_t41" reading_order_no="41" segment_no="7" tag_type="text">ation of EL concentrations with lipoprotein concentrations,</text>
<text top="512" left="45" width="243" height="8" font="font1" id="p1_t42" reading_order_no="42" segment_no="7" tag_type="text">other cardiovascular risk factors and coronary artery calci-</text>
<text top="523" left="45" width="243" height="8" font="font1" id="p1_t43" reading_order_no="43" segment_no="7" tag_type="text">ﬁcation (CAC), a noninvasive measure of coronary athero-</text>
<text top="534" left="45" width="67" height="8" font="font1" id="p1_t44" reading_order_no="44" segment_no="7" tag_type="text">sclerosis [15–17].</text>
<text top="558" left="45" width="41" height="10" font="font0" id="p1_t45" reading_order_no="45" segment_no="9" tag_type="title">Methods</text>
<text top="573" left="45" width="62" height="9" font="font2" id="p1_t46" reading_order_no="46" segment_no="11" tag_type="title">Study Protocol</text>
<text top="586" left="54" width="234" height="8" font="font1" id="p1_t47" reading_order_no="47" segment_no="12" tag_type="text">SIRCA is a cross-sectional study of asymptomatic individ-</text>
<text top="597" left="45" width="243" height="8" font="font1" id="p1_t48" reading_order_no="48" segment_no="12" tag_type="text">uals and their families designed to investigate novel bio-</text>
<text top="608" left="45" width="243" height="8" font="font1" id="p1_t49" reading_order_no="49" segment_no="12" tag_type="text">markers and genetic factors associated with coronary</text>
<text top="619" left="45" width="243" height="8" font="font1" id="p1_t50" reading_order_no="50" segment_no="12" tag_type="text">atherosclerosis. The study design and initial ﬁndings have</text>
<text top="630" left="45" width="243" height="8" font="font1" id="p1_t51" reading_order_no="51" segment_no="12" tag_type="text">previously been published [18,19]. Brieﬂy, persons were</text>
<text top="641" left="45" width="243" height="8" font="font1" id="p1_t52" reading_order_no="52" segment_no="12" tag_type="text">eligible for SIRCA if they had a family history of premature</text>
<text top="652" left="45" width="243" height="8" font="font1" id="p1_t53" reading_order_no="53" segment_no="12" tag_type="text">coronary artery disease (CAD), were free of clinical CAD, and</text>
<text top="663" left="45" width="243" height="8" font="font1" id="p1_t54" reading_order_no="54" segment_no="12" tag_type="text">were men, 20–75 years of age or women, 30–75 years.</text>
<text top="674" left="45" width="243" height="8" font="font1" id="p1_t55" reading_order_no="55" segment_no="12" tag_type="text">Exclusion criteria included other major CAD risk factors:</text>
<text top="685" left="45" width="243" height="8" font="font1" id="p1_t56" reading_order_no="56" segment_no="12" tag_type="text">known diabetes, total cholesterol higher than 300 mg/dl,</text>
<text top="696" left="45" width="243" height="8" font="font1" id="p1_t57" reading_order_no="57" segment_no="12" tag_type="text">cigarette smoking of one pack or more per day, or blood</text>
<text top="707" left="45" width="243" height="8" font="font1" id="p1_t58" reading_order_no="58" segment_no="12" tag_type="text">pressure higher than 160/100 mm Hg. The University of</text>
<text top="719" left="45" width="243" height="8" font="font1" id="p1_t59" reading_order_no="59" segment_no="12" tag_type="text">Pennsylvania Institutional Review Board approved the study</text>
<text top="50" left="306" width="243" height="8" font="font1" id="p1_t60" reading_order_no="60" segment_no="2" tag_type="text">protocol. Informed consent was obtained from each partic-</text>
<text top="61" left="306" width="243" height="8" font="font1" id="p1_t61" reading_order_no="61" segment_no="2" tag_type="text">ipant. This report focuses on 858 random unrelated</text>
<text top="72" left="306" width="243" height="8" font="font1" id="p1_t62" reading_order_no="62" segment_no="2" tag_type="text">individuals from the SIRCA in whom plasma EL concen-</text>
<text top="83" left="306" width="96" height="8" font="font1" id="p1_t63" reading_order_no="63" segment_no="2" tag_type="text">trations were measured.</text>
<text top="101" left="306" width="91" height="9" font="font2" id="p1_t64" reading_order_no="64" segment_no="4" tag_type="title">Evaluated Parameters</text>
<text top="113" left="315" width="234" height="8" font="font1" id="p1_t65" reading_order_no="65" segment_no="5" tag_type="text">Participants were assessed at the General Clinical Research</text>
<text top="124" left="306" width="243" height="8" font="font1" id="p1_t66" reading_order_no="66" segment_no="5" tag_type="text">Center in the University of Pennsylvania Medical Center after</text>
<text top="135" left="306" width="243" height="8" font="font1" id="p1_t67" reading_order_no="67" segment_no="5" tag_type="text">a 12-h overnight fast. A questionnaire was administered;</text>
<text top="146" left="306" width="243" height="8" font="font1" id="p1_t68" reading_order_no="68" segment_no="5" tag_type="text">height, weight, waist circumference, and blood pressure were</text>
<text top="157" left="306" width="186" height="8" font="font1" id="p1_t69" reading_order_no="69" segment_no="5" tag_type="text">obtained; and 30 ml of whole blood was drawn (</text>
<text top="157" left="492" width="4" height="8" font="font3" id="p1_t70" reading_order_no="70" segment_no="5" tag_type="text">‘‘</text>
<text top="157" left="497" width="48" height="8" font="font1" id="p1_t71" reading_order_no="71" segment_no="5" tag_type="text">pre-heparin</text>
<text top="157" left="545" width="4" height="8" font="font3" id="p1_t72" reading_order_no="72" segment_no="5" tag_type="text">’’</text>
<text top="168" left="306" width="243" height="8" font="font1" id="p1_t73" reading_order_no="73" segment_no="5" tag_type="text">plasma) into EDTA-containing tubes. In a subset of individ-</text>
<text top="179" left="306" width="22" height="8" font="font1" id="p1_t74" reading_order_no="74" segment_no="5" tag_type="text">uals (</text>
<text top="179" left="329" width="5" height="8" font="font4" id="p1_t75" reading_order_no="75" segment_no="5" tag_type="text">n</text>
<text top="178" left="337" width="7" height="9" font="font5" id="p1_t76" reading_order_no="76" segment_no="5" tag_type="text">¼</text>
<text top="179" left="347" width="202" height="8" font="font1" id="p1_t77" reading_order_no="77" segment_no="5" tag_type="text">510), blood was drawn 10 min after intravenous</text>
<text top="190" left="306" width="243" height="8" font="font1" id="p1_t78" reading_order_no="78" segment_no="5" tag_type="text">administration of heparin (60 units per kilogram body</text>
<text top="201" left="306" width="243" height="8" font="font1" id="p1_t79" reading_order_no="79" segment_no="5" tag_type="text">weight). After the blood was centrifuged, the plasma was</text>
<text top="212" left="306" width="98" height="8" font="font1" id="p1_t80" reading_order_no="80" segment_no="5" tag_type="text">removed and stored at</text>
<text top="212" left="415" width="9" height="8" font="font1" id="p1_t81" reading_order_no="81" segment_no="5" tag_type="text">80</text>
<text top="212" left="429" width="3" height="8" font="font6" id="p1_t82" reading_order_no="82" segment_no="5" tag_type="text">8</text>
<text top="212" left="432" width="57" height="8" font="font1" id="p1_t83" reading_order_no="83" segment_no="5" tag_type="text">C until use (</text>
<text top="212" left="489" width="4" height="8" font="font3" id="p1_t84" reading_order_no="84" segment_no="5" tag_type="text">‘‘</text>
<text top="212" left="493" width="51" height="8" font="font1" id="p1_t85" reading_order_no="85" segment_no="5" tag_type="text">post-heparin</text>
<text top="212" left="545" width="4" height="8" font="font3" id="p1_t86" reading_order_no="86" segment_no="5" tag_type="text">’’</text>
<text top="223" left="306" width="243" height="8" font="font1" id="p1_t87" reading_order_no="87" segment_no="5" tag_type="text">plasma). Plasma total cholesterol, HDL cholesterol, and</text>
<text top="234" left="306" width="243" height="8" font="font1" id="p1_t88" reading_order_no="88" segment_no="5" tag_type="text">triglyceride concentrations were measured enzymatically on</text>
<text top="245" left="306" width="243" height="8" font="font1" id="p1_t89" reading_order_no="89" segment_no="5" tag_type="text">a Cobas Fara II (Roche Diagnostic Systems, Indianapolis,</text>
<text top="257" left="306" width="243" height="8" font="font1" id="p1_t90" reading_order_no="90" segment_no="5" tag_type="text">Indiana, United States) using Sigma reagents (Sigma, St.</text>
<text top="268" left="306" width="243" height="8" font="font1" id="p1_t91" reading_order_no="91" segment_no="5" tag_type="text">Louis, Missouri, United States) in a Centers for Disease</text>
<text top="279" left="306" width="243" height="8" font="font1" id="p1_t92" reading_order_no="92" segment_no="5" tag_type="text">Control-standardized lipid laboratory. LDL cholesterol was</text>
<text top="290" left="306" width="163" height="8" font="font1" id="p1_t93" reading_order_no="93" segment_no="5" tag_type="text">calculated using the Friedewald formula.</text>
<text top="301" left="315" width="234" height="8" font="font1" id="p1_t94" reading_order_no="94" segment_no="6" tag_type="text">Post-heparin plasma samples in EDTA were analyzed for</text>
<text top="312" left="306" width="243" height="8" font="font1" id="p1_t95" reading_order_no="95" segment_no="6" tag_type="text">lipoprotein subclasses by nuclear magnetic resonance (NMR)</text>
<text top="323" left="306" width="243" height="8" font="font1" id="p1_t96" reading_order_no="96" segment_no="6" tag_type="text">[20–22] (LipoSciences, Raleigh, North Carolina, United</text>
<text top="334" left="306" width="243" height="8" font="font1" id="p1_t97" reading_order_no="97" segment_no="6" tag_type="text">States). The NMR method uses the characteristic proton</text>
<text top="345" left="306" width="243" height="8" font="font1" id="p1_t98" reading_order_no="98" segment_no="6" tag_type="text">signals broadcast by lipoprotein subclasses to determine both</text>
<text top="356" left="306" width="243" height="8" font="font1" id="p1_t99" reading_order_no="99" segment_no="6" tag_type="text">the size and the quantity of each size of lipoprotein. A</text>
<text top="367" left="306" width="243" height="8" font="font1" id="p1_t100" reading_order_no="100" segment_no="6" tag_type="text">summary of the reporting format can be found at http://www.</text>
<text top="378" left="306" width="243" height="8" font="font1" id="p1_t101" reading_order_no="101" segment_no="6" tag_type="text">liposcience.com. The ten subclasses (and their size ranges)</text>
<text top="389" left="306" width="243" height="8" font="font1" id="p1_t102" reading_order_no="102" segment_no="6" tag_type="text">routinely used are: large very low-density lipoprotein (VLDL)</text>
<text top="400" left="306" width="243" height="8" font="font1" id="p1_t103" reading_order_no="103" segment_no="6" tag_type="text">(60–200 nm), intermediate VLDL (35–60 nm), small VLDL</text>
<text top="411" left="306" width="243" height="8" font="font1" id="p1_t104" reading_order_no="104" segment_no="6" tag_type="text">(27–35 nm), IDL (23–27 nm), large low-density lipoprotein</text>
<text top="422" left="306" width="243" height="8" font="font1" id="p1_t105" reading_order_no="105" segment_no="6" tag_type="text">(LDL) (21.3–23 nm), intermediate LDL (19.8–21.2 nm), small</text>
<text top="433" left="306" width="243" height="8" font="font1" id="p1_t106" reading_order_no="106" segment_no="6" tag_type="text">LDL (18.3–19.7 nm), large HDL (8.8–13.0 nm), intermediate</text>
<text top="444" left="306" width="191" height="8" font="font1" id="p1_t107" reading_order_no="107" segment_no="6" tag_type="text">HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm).</text>
<text top="455" left="315" width="234" height="8" font="font1" id="p1_t108" reading_order_no="108" segment_no="8" tag_type="text">Electron beam computed tomography was performed on</text>
<text top="466" left="306" width="243" height="8" font="font1" id="p1_t109" reading_order_no="109" segment_no="8" tag_type="text">an Imatron C-150 XP/LXP Evolution scanner (Imatron, San</text>
<text top="478" left="306" width="243" height="8" font="font1" id="p1_t110" reading_order_no="110" segment_no="8" tag_type="text">Francisco, California, United States) connected to a Magic-</text>
<text top="489" left="306" width="243" height="8" font="font1" id="p1_t111" reading_order_no="111" segment_no="8" tag_type="text">View workstation for volumetric image reconstruction.</text>
<text top="500" left="306" width="243" height="8" font="font1" id="p1_t112" reading_order_no="112" segment_no="8" tag_type="text">Using ECG triggering with the individual in a supine</text>
<text top="511" left="306" width="243" height="8" font="font1" id="p1_t113" reading_order_no="113" segment_no="8" tag_type="text">position, 40 contiguous, 3 mm-thick axial slices were</text>
<text top="522" left="306" width="243" height="8" font="font1" id="p1_t114" reading_order_no="114" segment_no="8" tag_type="text">acquired just below the carina through the apex of the</text>
<text top="533" left="306" width="243" height="8" font="font1" id="p1_t115" reading_order_no="115" segment_no="8" tag_type="text">heart. Global CAC scores were determined according to the</text>
<text top="544" left="306" width="101" height="8" font="font1" id="p1_t116" reading_order_no="116" segment_no="8" tag_type="text">method of Agatston [23].</text>
<text top="562" left="306" width="220" height="9" font="font2" id="p1_t117" reading_order_no="117" segment_no="10" tag_type="title">Sandwich Enzyme-Linked Immunosorbent Assay for</text>
<text top="574" left="306" width="43" height="9" font="font2" id="p1_t118" reading_order_no="118" segment_no="10" tag_type="title">Human EL</text>
<text top="586" left="315" width="234" height="8" font="font1" id="p1_t119" reading_order_no="119" segment_no="13" tag_type="text">Detailed information on the development and quality</text>
<text top="597" left="306" width="243" height="8" font="font1" id="p1_t120" reading_order_no="120" segment_no="13" tag_type="text">control of the sandwich ELISA can be found in Protocol S1.</text>
<text top="608" left="306" width="243" height="8" font="font1" id="p1_t121" reading_order_no="121" segment_no="13" tag_type="text">The wells of a 96-well microtiter plate were coated with rabbit</text>
<text top="619" left="306" width="243" height="8" font="font1" id="p1_t122" reading_order_no="122" segment_no="13" tag_type="text">anti-human EL antibody. Various concentrations of puriﬁed</text>
<text top="630" left="306" width="243" height="8" font="font1" id="p1_t123" reading_order_no="123" segment_no="13" tag_type="text">recombinant human EL in phosphate-buffered saline con-</text>
<text top="641" left="306" width="243" height="8" font="font1" id="p1_t124" reading_order_no="124" segment_no="13" tag_type="text">taining 1% BSA were added to the wells as a standard. Plasma</text>
<text top="652" left="306" width="243" height="8" font="font1" id="p1_t125" reading_order_no="125" segment_no="13" tag_type="text">samples were diluted 1:10 in phosphate-buffered saline and</text>
<text top="663" left="306" width="243" height="8" font="font1" id="p1_t126" reading_order_no="126" segment_no="13" tag_type="text">applied to the wells. Speciﬁcally bound protein was incubated</text>
<text top="674" left="306" width="243" height="8" font="font1" id="p1_t127" reading_order_no="127" segment_no="13" tag_type="text">with biotin-conjugated rabbit anti-human EL antibody,</text>
<text top="685" left="306" width="243" height="8" font="font1" id="p1_t128" reading_order_no="128" segment_no="13" tag_type="text">followed by streptavidin-horseradish peroxidase conjugate,</text>
<text top="696" left="306" width="243" height="8" font="font1" id="p1_t129" reading_order_no="129" segment_no="13" tag_type="text">and detection with o-phenylenediamine. The reaction was</text>
<text top="707" left="306" width="243" height="8" font="font1" id="p1_t130" reading_order_no="130" segment_no="13" tag_type="text">stopped with 2.5 M sulfuric acid and the plate read at 490 nm.</text>
<text top="719" left="306" width="243" height="8" font="font1" id="p1_t131" reading_order_no="131" segment_no="13" tag_type="text">A standard curve of 490 nm absorbance versus the known</text>
<text top="742" left="69" width="133" height="7" font="font7" id="p1_t132" reading_order_no="132" segment_no="14" tag_type="text">PLoS Medicine | www.plosmedicine.org</text>
<text top="742" left="411" width="138" height="7" font="font7" id="p1_t133" reading_order_no="134" segment_no="15" tag_type="text">February 2006 | Volume 3 | Issue 2 | e22</text>
<text top="742" left="289" width="16" height="7" font="font7" id="p1_t134" reading_order_no="133" segment_no="16" tag_type="text">0246</text>
<text top="26" left="454" width="95" height="7" font="font7" id="p1_t135" reading_order_no="0" segment_no="0" tag_type="title">EL and Metabolic Syndrome</text>
</page>
</pdf2xml>
